The next EAN Autumn School will take in place in Loutraki, Greece, from October 17-20, 2019. The programme for the Autumn School is now available online on the EAN website covering the topics of cognitivie dysfuntion and headache. If you would like to attend the workshop, you need apply soon. The deadline for applications is July 31, 2019

Interview with Prof. Claudio Baracchini - President of the ESNCH Prof. Dafin Muresanu interviews President of the ESNCH, Prof. Claudio Baracchini

Successful collaboration between the EAN and the International Neuro-urology Society (INUS) at the 7th annual International Neuro-urology Meeting in Zurich. The 7th International Neuro-urology Meeting was held in January 2019 and for the first time, a dedicated Neurosciences workshop was held in collaboration with the EAN. The half-day workshop on Thursday 24 January 2019 began with imaging research and our understanding of the neural control of the lower urinary tract, and included topics such as a review of the neural networks responsible for lower urinary tract control, potential brain imaging biomarkers to evaluate therapeutic interventions for LUT dysfunction and Neuroimaging of functional recovery in SCI. 

Please find below articles from Norwegian authors that were published in the European Journal of Neurology.

Migraine is the number one cause of disability affecting people under the age of fifty years  ( the group with the highest contribution to workforce worldwide) making one of the highest negative economic impacts globally(1).  According to the latest analysis from the GBD study, almost 3 billion people had a headache disorder in 2016: 1.89 billion had a diagnosis of tension-type headache, and 1.04 billion had a diagnosis of migraine(2). Migraine was responsible for 45.12 million years of life lived with disability (YLD), with a peak in prevalence in women between 15 and 49 years(3). One in seven suffer from this disabling, least respected, worst managed, least recognised complex brain disorder worldwide(5).

Governmental Expert Group on Dementia holds second meeting The European Group of Governmental Experts on Dementia held its second meeting on 17 and 18 June 2019 in Amsterdam, The Netherlands. 20 European countries were represented at the meeting, in addition to representatives from the 2nd European Joint Action on Dementia (Act on Dementia/DEM2), the World Health Organization (WHO) and Alzheimer Europe.

A Memorandum of Understanding (MoU) with the European Society of Neurosonology and Cerebral Hemodynamics (ESNCH) was signed in June 2019. The ESNCH is the most successful neurosonology group worldwide bringing together the world’s experts, thus representing an excellent platform for young researchers to present their work, gain experience and start a scientific collaboration.

Task Force Regulatory Affairs and Medical Devices Workshop on Medical Device Registries: The BioMed Alliance organised a joint workshop on Medical Device Registries with the European Society of Cardiology (ESC) and the European Federation of National Associations of Orthopaedics and Traumatology (EFORT) on 17 June. The programme included speakers from the European Commission, member societies, a notified body, industry, the European Medicines Agency and experts who manage successful registries across Europe.

EFNA goes global and attends the WHA – World Health Assembly UN Geneva Headquarters from May 20 – 28 2019. Diseases know no borders. Only by truly pooling our resources and going beyond our individual disease areas, our constituencies and countries, do we stand a chance of adequately addressing the challenges of ill-health and inequalities.

The guideline education and Cost-Conscious Healthcare (CoCoCare) programme was launched prior to the 5th EAN Congress in Oslo. 

I am really grateful to the European Academy of Neurology for having granted my training research fellowship at the Department of Clinical Neurosciences of the University of Cambridge. During the final year of my residency in Neurology at the Sapienza University of Rome, I had the great honour to join the research group of Professor Mariagrazia Spillantini, who discovered - in 1997 - the presence of alpha-synuclein in Lewy bodies, the pathological hallmarks of Parkinson’s Disease.

It is my great pleasure to be invited to introduce myself to you in my new role as editor of EAN Pages, starting at our Congress in Oslo. I am a neurologist based in Sheffield in the UK, running busy general and neuromuscular clinics, with a research interest in motor neuron disease. First of all, I want to thank my predecessor and friend, Professor Elena Moro, for leading us to our current position of strength at EAN Pages.

For July 2019, we have selected a scientific paper: RESTART Collaboration. Effects of antiplatelet therapy after stroke due to intracerebral haemorrhage: a randomised open label trial. Lancet 2019; May 21 [Epub ahead of print]

Norway is located in the western and northern part of Scandinavia, and it is well known for its beautiful scenery with fjords and waterfalls along the coastline, its mountainous wilderness, and for Arctic regions with northern lights in the winter and midnight sun during the summer. Norway is one of Europe's most sparsely populated countries with 5.2 million people in a land area of 385,802 km2. The most densely populated area is around the city of Oslo in the south-east of the country. Oslo, the Norway’s capital, is the fastest-growing capital in Europe.

There is need for automated seizure detection using wearable devices, to decrease the morbidity and mortality associated with seizures, especially with generalized tonic-clonic seizures (GTCS) and to provide objective data on seizure-occurrence...